Article
Targeting molecular alterations in non-small-cell lung cancer: what's next?
Personalized medicine - 1 Jul 2022
López-Castro Rafael, García-Peña Tania, Mielgo-Rubio Xabier, Riudavets Mariona, Teixidó Cristina, Vilariño Noelia, Couñago Felipe, Mezquita Laura
Abstract excerpt
In recent years, major advances have been achieved in our understanding of non-small-cell lung cancer (NSCLC) with oncogenic driver alterations and in the specific treatment of these with tyrosine kinase inhibitors. Currently, state-of-the-art management of patients with NSCLC (particularly adenocarcinoma or non-adenocarcinoma but with mild tobacco exposure) consists of the determination of EGFR, ALK, ROS1 and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.